It has been demonstrated that the protumoral phenotype of TAMs can be mitigated by suppressing the expression of M2 phenotype markers, CD163 and CD209, in ovarian cancer A2780 cells [53]. This evidence concerns the gene CD209 and ovarian carcinoma.